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Abstract
Background: To investigate whether whole-liver radiotherapy (RT) is beneficial in end-stage colorectal cancer with
massive liver metastases and severe hepatic dysfunction.
Methods: Between June 2004 and July 2008, 10 colorectal cancer patients, who exhibited a replacement of over
three quarters of their normal liver by metastatic tumors and were of Child-Pugh class B or C in liver function with
progressive disease after undergoing chemotherapy, underwent whole-liver RT. RT was administered using
computed tomography-based three-dimensional planning and the median dose was 21 Gy (range, 21-30) in seven
fractions. Improvement in liver function tests, defined as a decrease in the levels within 1 month after RT, symptom
palliation, toxicity, and overall survival were analyzed retrospectively.
Results: Levels of alkaline phosphatase, total bilirubin, aspartate transaminase, and alanine transaminase improved
in 8, 6, 9, and all 10 patients, respectively, and the median reduction rates were 42%, 68%, 50%, and 57%,
respectively. Serum carcinoembryonic antigen level decreased after RT in three of four assessable patients. For all
patients, pain levels decreased and acute toxicity consisted of nausea/vomiting of grade ≤ 2. Further
chemotherapy became possible in four of 10 patients. Mean survival after RT was 80 ± 80 days (range, 20-289);
mean survival for four patients who received post-RT chemotherapy was 143 ± 100 days (range, 65-289), versus
38 ± 16 days (range, 20-64) for the six patients who did not receive post-RT chemotherapy (p = 0.127).
Conclusions: Although limited by small case number, this study demonstrated a possible role of whole-liver RT in
improving hepatic dysfunction and delaying mortality from hepatic failure for end-stage colorectal cancer patients
with massive liver metastases. Further studies should be followed to confirm these findings.
Background
Most colorectal cancer deaths a r ea t t r i b u t a b l et od i s t a n t
metastases, frequently in the liver. At diagnosis, approxi-
mately 20% of colorectal cancer patients have liver
metastases, and about half of patients initially diagnosed
with localized disease develop metachronous liver metas-
tases [1-3]. Curative resection of liver metastasis is possi-
ble in fewer than 25% of patients and two-thirds of
patients receiving liver resections show liver disease
recurrence within 2 years [4-7]. Systemic and hepatic
arterial chemotherapy are the principal treatments
for unresectable or recurrent colorectal cancer liver
metastasis [5,8]. Unfortunately, a subset of these patients
progress to end-stage status, in which their livers are
replaced by metastatic tumors. This eventually leads to
hepatic failure and death [3,9]. For these patients, further
chemotherapy cannot be given due to severe hepatic dys-
function or metastatic tumors which became refractory
to chemotherapy.
Palliative whole-liver radiotherapy (RT) has been an
effective treatment in symptom control for intra-hepatic
tumors including colorectal cancer liver metastases
[3,10]. Recent studies, using advanced RT technologies,
have investigated the delivery of escalated radiation
doses to partial liver volumes and administering concur-
rent chemotherapy to increase the effectiveness of RT
on the tumor [5,11-15]. However, for end-stage colorec-
tal cancer patients with massive liver metastases and
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provided unless associated symptoms are severe and
uncontrollable. If RT can improve advanced hepatic dys-
function, further chemotherapy treatment might become
possible and patient mortality due to hepatic failure
could be postponed.
The present study explored the efficacy of palliative
whole-liver RT for end-stage colorectal cancer patients
with massive liver metastases and impending hepatic fail-
ure on liver function improvement and patient survival.
Methods
Patients
The institutional review board of the National Cancer
Center approved this study. Informed consent was not
required because the study was retrospective in nature.
Between June 2004 and July 2008, 10 end-stage colorectal
cancer patients with massive liver metastases and
advanced hepatic dysfunction who received whole-liver
RT were retrospectively analyzed. Inclusion criteria were
massive liver metastases defined as the replacement of
over three-quarters of the liver by metastatic tumors, and
advanced hepatic dysfunction defined as Child-Pugh
class B or C. Patient characteristics are shown in Table 1.
Nine patients were females and the median age was
57 years (range, 42-73). All patients were in the Eastern
Cooperative Oncology Group performance scale range of
2-4. The principal symptoms prior to RT were mild-to-
moderate abdominal pain and distension resulting from
the growing liver metastases.
Primary tumor sites were the colon and rectum in
seven and three patients, respectively. At the initial diag-
nosis of primary colorectal cancer, all patients exhibited
liver metastases, and eight of them also had extra-hepatic
metastases. Surgical resection for primary colorectal
tumors was performed with curative intent in four
(No. 1, 2, 4, 5) and palliative in four patients (No. 3, 7, 8,
9). Surgery was not performed on either the primary
tumor or on the liver in the remaining two patients (No.
6, 10); because multiple organ metastases were found at
initial diagnosis, chemotherapy alone was given. In two
of the patients who received synchronous surgery for
both primary tumors and liver metastasis, metastatic dis-
e a s er e c u r r e di nt h el i v e ra t1 3( N o .2 )a n d3m o n t h s
(No. 4). The median interval from initial liver metastasis
diagnosis to liver RT was 12 months (range, 4-30). The
median serum carcinoembryonic antigen (CEA) level
measured 1 month prior to RT was 4092 ng/mL (range,
373-11858). Child-Pugh classification before RT was
class B in eight patients and class C in the remaining two
patients. All patients received multiple cycles (median,
13; range, 4-32) of chemotherapy before RT. This
included various combinations of 5-fluorouracil, leucov-
orin, capecitabine, irinotecan, oxaliplatin, S-1, uracil-
tegafur, bevacizumab, and cetuximab. Patients were
referred for liver RT when they became refractory to che-
motherapy or could not tolerate further chemotherapy
due to hepatic dysfunction or medical comorbidities. At
the time of liver RT, nine patients had extra-hepatic dis-
ease with metastases in the para-aortic lymph node, peri-
toneum, lung, pelvis, bone, or supraclavicular lymph
nodes.
Radiotherapy
All patients were placed in the supine position with
arms above their heads and immobilized using an alpha-
cradle device to improve the setup reproducibility dur-
ing the planning and treatments and to facilitate the use
of lateral radiation ports. Computed tomography data
were transferred to a three-dimensional conformal RT
Table 1 Patient characteristics
Patient
No.
Age
(yr)
Gender Primary
tumor
site
Initial
stage
Surgical
resection
Extrahepatic
metastasis at
initial
diagnosis
Interval from
liver
metastasis to
RT (mo)
Extrahepatic
metastasis at
the time of RT
Serum
CEA*
before RT
(ng/mL)
Child-Pugh
classification
before RT
Primary Liver
1 47 F Rectum pT3N0M1 Y N Y 30 Y 1727 B
2 57 M Colon pT3N0M1 Y Y Y 18 Y 1481 C
3 53 F Colon pT4N1M1 Y N Y 18 Y 11858 B
4 42 F Rectum pT3N2M1 Y Y Y 13 Y 5198 B
5 61 F Colon pT4N2M1 Y N N 4 N 7629 B
6 68 F Colon cT3N2M1 N N Y 6 Y 10
† C
7 45 F Colon pT3N2M1 Y N N 26 Y 2103 B
8 57 F Colon pT3N2M1 Y N Y 11 Y 373 B
9 70 F Colon pT3N0M1 Y N Y 11 Y 6424 B
10 73 F Rectum cT3N2M1 N N Y 8 Y 4092 B
*Carcinoembryonic antigen (normal range, ≤ 5n g / m L )
†Measured 3 months before RT. Levels in other patients were assessed 1 month before RT
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ogy, Chico, CA). For each patient, clinical target volume
including the entire liver metastatic tumors and neigh-
boring organs, such as stomach, duodenum, kidneys and
spinal cord, were contoured on each slice and recon-
structed three-dimensionally. The planning target
volume included almost the entire liver, without a mar-
gin, to minimize radiation damage to neighboring nor-
mal organs. All patients were asked to respire shallowly
to minimize target motion. Two radiation portals were
used: a left anterior oblique and a right posterior obli-
que beam (Figure 1). RT was administered via a linear
accelerator that emits X-rays of 15 MV. A daily dose of
3 Gy was administered five times per week to deliver a
total dose of 21 Gy; this scheme was determined based
o nt h eR a d i a t i o nT h e r a p yO n c o l o g yG r o u ps t u d yf o r
hepatocellular carcinoma [16]. Chemotherapy was not
administered during RT, except that one patient, No. 7,
received concurrent cetuximab.
Analysis
To evaluate the effect of RT on liver function improve-
ment, liver function tests, including alkaline phosphatase
(ALP), total bilirubin (TB), aspartate transaminase
(AST), alanine transaminase (ALT), and serum CEA
levels before and after RT, were analyzed. Improvement
in these values was defined as any decrease in the levels
within 1 month after RT. The reduction rate was calcu-
lated between the level before RT and the lowest level
recorded within 1 month after RT. Overall survival was
calculated from the first day of RT to death and com-
pared using the t-test. Treatment toxicity was evaluated
using the Radiation Therapy Oncology Group radiation
morbidity scoring criteria. Statistical tests were per-
formed using the SPSS software (ver. 14.0; SPSS Inc.,
Chicago, IL, USA). A p-value of < 0.05 was deemed to
indicate statistical significance.
Results
T r e a t m e n tr e s u l t sa r es h o w ni nT a b l e2 .N i n ep a t i e n t s
received 21 Gy in seven fractions and one patient
received 30 Gy in 10 fractions. All patients experienced
a decrease in pain levels, as measured using numeric
rating scales. Treatment response based on abdomino-
pelvic computed tomography was assessed in four
patients: three (No. 2, 5, 7) showed minimal responses,
while one (No. 1) had no response. Treatment-related
acute toxicity consisted mostly of nausea/vomiting,
which was grade 1 or 2.
The levels of ALP, TB, and AST were above normal
prior to RT in all patients (median 583 IU/L (range, 306-
1246), median 6.5 mg/dL (range, 1.3-36.7), and median
118 IU/L (range, 42-250), respectively). After RT, ALP,
TB, and AST levels decreased in eight (80%), six (60%),
and nine (90%) patients, respectively, and the median
reduction rates were 42% (range, 14-79%), 68% (range,
29-75%), and 50% (range, 22-90%), respectively. ALT
level was higher than normal prior to RT in eight patients
(median, 43 IU/L; range, 25-123). After RT, ALT level
improved in all patients and the median reduction rate
was 57% (range, 37-84%). Serum CEA levels 1 month
after RT were available for four patients; these levels
decreased by 223-779 ng/mL in three patients (No. 1, 5,
7) and increased by 271 ng/mL in one patient (No. 2).
The serum albumin (g/dL) change was small (within ±
15%) in all patients, and four of five patients with pro-
thrombin time (international normalized ratio) specified
within 1 month after RT showed a decrease (10-25%) in
that value. Child-Pugh score was specified in five patients
within 1 month after RT; it decreased (from -1 to -3) in
three and was unchanged in two. The duration of liver
function palliation varied according to the different mea-
sures of liver function tests, and the improved liver func-
tions deteriorated before the patients died. As an
example, the total bilirubin level improvement lasted for
1 (No. 4, 6), 2 (No. 1, 7), 3 (No. 2), or 7 months (No. 5)
in six patients with post-RT improvement in this value.
Four patients received post-RT chemotherapy, which
was decided by medical oncologists based on the perfor-
mance status of the patients and the availability of effec-
tive agents: seven cycles of bevacizumab (No. 1), nine
cycles of 5-fluorouracil, leucovorin, and oxaliplatin
(No. 2), 19 cycles of cetuximab and nine cycles of irino-
tecan (No. 5), or four cycles of cetuximab (No. 7). For
all patients, the mean survival times from the initial sur-
gery or diagnosis of primary colorectal tumor and from
Figure 1 Central axial computed tomography slice showing the
three-dimensional conformal radiotherapy plan. The treatment
target was the whole-liver. Two radiation fields, with left anterior
oblique and right posterior oblique beams, both consisting of 15
MV X-rays, were used to cover the target.
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Page 3 of 6RT were 19 ± 11 months (range, 7-42) and 80 ± 80 days
(range, 20-289), respectively. The mean survival times
from RT in the four patients who received post-RT che-
motherapy and the remaining six patients who did not
were 143 ± 100 days (range, 65-289) and 38 ± 16 days
(range, 20-64), respectively (p = 0.127).
Discussion
Medical interventions that can possibly affect patient life
span are often an issue in medial multidisciplinary deci-
sion-making for end-stage cancer patients who have
only a few remaining days of life [17,18]. Patients in this
study had end-stage colorectal cancer with multiple
organ metastases, including massive liver metastases
refractory to multiple chemotherapeutic drugs and liver
f u n c t i o nh a dp r o g r e s s e dt oa lmost hepatic failure. Per-
formance status was unfavorable. Although pain asso-
ciated with massive liver metastases was not severe,
because of analgesic management and supportive care,
we provided short-course palliative whole-liver RT and
the advanced liver dysfunction was improved in most of
the patients. Moreover, four patients were able to
receive further chemotherapy due to improvement in
liver function post-RT and we experienced delayed mor-
tality in these end-stage colorectal cancer patients with
massive liver metastases.
When survival time is estimated to be weeks-to-months,
estimating life expectancy is difficult [19]. Kemeny et al.
[9] compared hepatic arterial infusion versus systemic
therapy for colorectal cancer patients with liver metastasis,
and the independent prognostic factors for survival
included percent liver involvement, synchronous disease,
performance status, number of liver lesions, baseline CEA,
and the levels of ALP and albumin. Wang et al. [20] ana-
lyzed predictors of survival after hepatic resection in
colorectal cancer patients with liver metastasis, and they
reported age, primary tumor grade, comorbidity score, and
chemotherapy after liver resection to be significant prog-
nostic factors. For patients in our study who exhibited sev-
eral of these poor prognostic factors, their life expectancy
was estimated to be less than several weeks. Usually, only
supportive care is provided for such patients.
Several previous studies have investigated the effective-
ness of whole-liver RT for the management of patients
with liver metastases. Most of the patients included in
these studies had liver metastases from colorectal pri-
maries following chemotherapy and were treated with a
total dose of 20-30 Gy at 1.5-3.0 Gy per fraction. Pain
relief was achieved in 50-90% of the patients and up to
50% experienced a decrease in liver size, with an improve-
ment in liver function tests [3,10]. More recent research
has been directed at methods to amplify the effects of
radiation on the tumor (hypoxic cell sensitizers and che-
motherapy) and to deliver radiation more selectively to the
target, while sparing the surrounding normal liver
[5,11-15]. Higher doses of radiation could safely be applied
to a hepatic lesion if functional liver tissue is spared from
the high prescription dose. However, both the disease and
patient status in these studies were more favorable than
those of the current study. In a study by Mohiuddin et al.
[11], which reported improvement in symptoms and survi-
val with an additional boost dose to the dominant disease
in colorectal cancer multiple liver metastases, Karnofsky
performance score ≥ 80 was in 75.6% (34/45) patients and
more than half of the patients had normal level of CEA
and liver function tests. Krishnan et al. [5] reported favor-
able survival in colorectal cancer multiple liver metastases
with increased RT dose targeting only the dominant
tumor. All patients had Karnofsky performance scores
≥ 70 and the median number of hepatic tumors was four
Table 2 Treatment results
Patient
No.
Dose (Gy)/
fraction
Alkaline
phosphatase
(35 - 104 IU/L)*
Total bilirubin
(0.2 - 1.2 mg/dL)*
Aspartate
transaminase
(0 - 40 IU/L)*
Alanine
transaminase
(0 - 40 IU/L)*
Post-RT chemo-
therapy
Survival
from RT
(day)
1 21/7
†N (306) Y (6.5 ® 2.2, 66%) Y (118 ® 69, 42%) Y (43 ® 27, 37%) Y 123
2 21/7
‡Y (1246 ® 350, 72%) Y (3.0 ® 1.6, 47%) Y (114 ® 29, 75%) Y (43 ® 7, 84%) Y 94
3 21/7 N (554) N (1.8) Y (152 ® 109, 28%) Y (30 ® 18, 40%) N 64
4 21/7 Y (432 ® 297, 31%) Y (1.7 ® 1.2, 29%) Y (60 ® 24, 60%) Y (35 ® 13, 63%) N 22
5 21/7 Y (415 ® 89, 79%) Y (3.2 ® 1.0, 69%) Y (197 ® 20, 90%) Y (80 ® 13, 84%) Y 289
6 21/7 Y (675 ® 366, 46%) Y (15.8 ® 4.2, 73%) Y (101 ® 33, 67%) Y (49 ® 23, 53%) N 44
7 30/10 Y (1093 ® 613, 44%) Y (36.7 ® 9.2, 75%) Y (250 ® 124, 50%) Y (123 ® 31,
75%)
Y6 5
8 21/7 Y (615 ® 376, 39%) N (1.3) Y (88 ® 69, 22%) Y (25 ® 15, 40%) N 34
9 21/7 Y (404 ® 348, 14%) N (7.0) N (42) Y (31 ® 19, 39%) N 44
10 21/7 Y (612 ® 500, 18%) N (8.4) Y (142 ® 107, 25%) Y (76 ® 30, 61%) N 20
*Normal range
†No improvement in liver function test. Level before RT in parentheses
‡Improvement in liver function test. Levels before and after RT, and the reduction rate in parentheses
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even for patients like those in the present study, who had
disseminated liver metastases and in whom the hepatic
functional reserve was totally exhausted, has not been pre-
viously assessed.
Systemic chemotherapy is the mainstay of treatment for
massive metastatic colorectal cancer. Currently, regimens
incorporating irinotecan, oxaliplatin, cetuximab, bevacizu-
mab, and fluoropyrimidine are used for colorectal cancer
liver metastasis. With the introduction of these new
agents, the median survival time has increased to 15-21
months with first-line therapy and 7-12 months with sec-
ond-line therapy [5,8,21]. Our patients had liver metastasis
at initial diagnosis. They received multiple cycles of che-
motherapy with or without liver metastasis resection, but
metastatic disease progressed in the livers that became
refractory to chemotherapy. Locoregional approaches,
such as hepatic artery infusion chemotherapy, chemoem-
bolization, cryotherapy, radiofrequency ablation, laser, and
microwave coagulation, have shown promising results in
these situations [3,5]. However, these options are limited
by tumor size, proximity to vascular or biliary structures
and the ability of patients to tolerate invasive procedures.
RT does not have these limitations and is applicable to
end-stage massive liver metastases with advanced hepatic
dysfunction. Its efficacy was shown by an improvement in
most of the liver function tests in all patients and a
decrease in serum CEA levels for three of four assessable
patients with acceptable morbidity. Because of improve-
ment in liver function, four patients could receive addi-
tional chemotherapy after liver RT. Although statistical
significance was not shown, due to the low statistical
power of small sample size, the median survival time of
patients who received chemotherapy after RT was longer
than those of patients who did not.
Conclusions
Although conclusions must be drawn carefully from a
single-institution experience with a small sample size,
our data suggest that short-course whole-liver RT can
improve symptoms and hepatic dysfunction in end-stage
colorectal cancer patients with massive liver metastases
and severe hepatic dysfunction, and subsequently pro-
long their survival with acceptable morbidity. Further
careful and larger scaled studies should be conducted to
clarify the efficacy of whole-liver RT for these end-stage
colorectal cancer patients with massive liver metastases.
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